Skip to main content

Molecular biomarkers in the context of focal therapy for prostate cancer: recommendations of a Delphi Consensus from the Focal Therapy Society.

Publication ,  Journal Article
Marra, G; Laguna, MP; Walz, J; Pavlovich, CP; Bianco, F; Gregg, J; Lebastchi, AH; Lepor, H; Macek, P; Rais-Bahrami, S; Robertson, C; Abreu, AL ...
Published in: Minerva Urol Nephrol
October 2022

BACKGROUND: Focal therapy (FT) for prostate cancer (PCa) is promising. However, long-term oncological results are awaited and there is no consensus on follow-up strategies. Molecular biomarkers (MB) may be useful in selecting, treating and following up men undergoing FT, though there is limited evidence in this field to guide practice. We aimed to conduct a consensus meeting, endorsed by the Focal Therapy Society, amongst a large group of experts, to understand the potential utility of MB in FT for localized PCa. METHODS: A 38-item questionnaire was built following a literature search. The authors then performed three rounds of a Delphi Consensus using DelphiManager, using the GRADE grid scoring system, followed by a face-to-face expert meeting. Three areas of interest were identified and covered concerning MB for FT, 1) the current/present role; 2) the potential/future role; 3) the recommended features for future studies. Consensus was defined using a 70% agreement threshold. RESULTS: Of 95 invited experts, 42 (44.2%) completed the three Delphi rounds. Twenty-four items reached a consensus and they were then approved at the meeting involving (N.=15) experts. Fourteen items reached a consensus on uncertainty, or they did not reach a consensus. They were re-discussed, resulting in a consensus (N.=3), a consensus on a partial agreement (N.=1), and a consensus on uncertainty (N.=10). A final list of statements were derived from the approved and discussed items, with the addition of three generated statements, to provide guidance regarding MB in the context of FT for localized PCa. Research efforts in this field should be considered a priority. CONCLUSIONS: The present study detailed an initial consensus on the use of MB in FT for PCa. This is until evidence becomes available on the subject.

Duke Scholars

Published In

Minerva Urol Nephrol

DOI

EISSN

2724-6442

Publication Date

October 2022

Volume

74

Issue

5

Start / End Page

581 / 589

Location

Italy

Related Subject Headings

  • Surveys and Questionnaires
  • Prostatic Neoplasms
  • Male
  • Humans
  • Delphi Technique
  • Consensus
  • Biomarkers
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Marra, G., Laguna, M. P., Walz, J., Pavlovich, C. P., Bianco, F., Gregg, J., … Focal Therapy Society, . (2022). Molecular biomarkers in the context of focal therapy for prostate cancer: recommendations of a Delphi Consensus from the Focal Therapy Society. Minerva Urol Nephrol, 74(5), 581–589. https://doi.org/10.23736/S2724-6051.20.04160-0
Marra, Giancarlo, Maria P. Laguna, Jochen Walz, Christian P. Pavlovich, Fernando Bianco, Justin Gregg, Amir H. Lebastchi, et al. “Molecular biomarkers in the context of focal therapy for prostate cancer: recommendations of a Delphi Consensus from the Focal Therapy Society.Minerva Urol Nephrol 74, no. 5 (October 2022): 581–89. https://doi.org/10.23736/S2724-6051.20.04160-0.
Marra G, Laguna MP, Walz J, Pavlovich CP, Bianco F, Gregg J, et al. Molecular biomarkers in the context of focal therapy for prostate cancer: recommendations of a Delphi Consensus from the Focal Therapy Society. Minerva Urol Nephrol. 2022 Oct;74(5):581–9.
Marra, Giancarlo, et al. “Molecular biomarkers in the context of focal therapy for prostate cancer: recommendations of a Delphi Consensus from the Focal Therapy Society.Minerva Urol Nephrol, vol. 74, no. 5, Oct. 2022, pp. 581–89. Pubmed, doi:10.23736/S2724-6051.20.04160-0.
Marra G, Laguna MP, Walz J, Pavlovich CP, Bianco F, Gregg J, Lebastchi AH, Lepor H, Macek P, Rais-Bahrami S, Robertson C, Rukstalis D, Salomon G, Ukimura O, Abreu AL, Barbe Y, Cathelineau X, Gandaglia G, George AK, Gomez Rivas J, Gupta RT, Lawrentschuk N, Kasivisvanathan V, Lomas D, Malavaud B, Margolis D, Matsuoka Y, Mehralivand S, Moschini M, Oderda M, Orabi H, Rastinehad AR, Remzi M, Schulman A, Shin T, Shiraishi T, Sidana A, Shoji S, Stabile A, Valerio M, Tammisetti VS, Phin Tan W, VAN DEN Bos W, Villers A, Willemse P-P, DE LA Rosette J, Polascik T, Sanchez-Salas R, Focal Therapy Society. Molecular biomarkers in the context of focal therapy for prostate cancer: recommendations of a Delphi Consensus from the Focal Therapy Society. Minerva Urol Nephrol. 2022 Oct;74(5):581–589.

Published In

Minerva Urol Nephrol

DOI

EISSN

2724-6442

Publication Date

October 2022

Volume

74

Issue

5

Start / End Page

581 / 589

Location

Italy

Related Subject Headings

  • Surveys and Questionnaires
  • Prostatic Neoplasms
  • Male
  • Humans
  • Delphi Technique
  • Consensus
  • Biomarkers